Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT01188486
Official study title

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Study summary

The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many patients are poor operative candidates or decline surgery. This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool to produce therapeutically useful computed tomography (CT) scans, using standard water-soluble iodinated compounds as the contrast agents.

Ask AI to explain this study
Start here

Key things to know

Main goalDevice Feasibility

This describes the study’s primary purpose.

What is being studiedStereotactic Body Radiation Therapy (SBRT) and Computed Tomography (CT)

Plus 5 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC) · Mesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 17, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Stanford University

Study sponsor

01
Study overview

What this study is about

Purpose
Device Feasibility
Study type
Interventional
Phase
Not applicable
Sponsor
Stanford University
Interventions being studied
Radiation: Stereotactic Body Radiation Therapy (SBRT); Radiation: Computed Tomography (CT); Device: Cyberknife; Device: Trilogy; Device: True Beam; Drug: Iohexol; Drug: Iodixanol
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→Mesothelioma→
Disease setting
Early-stage or resectable→
Treatment approach
Radiation therapy→Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Either:
  • Established primary lung cancer/ cancer metastatic to lung, OR
  • Lesion suspicious for malignancy in lung, according to the following criteria:
  • Histopathologically confirmed lung cancer or cancer metastatic to lung, OR
  • Plan for biopsy of suspicious lung mass based on imaging (growth on serial CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR
  • Known metastatic cancer, with metastases to the lung based on imaging
  • Age \> 18 years old
  • Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV)
  • No prior surgery, chemotherapy, or radiation for the current lung tumor
Reasons someone may not be able to joinExclusion criteria
  • Prior radiotherapy to thorax
  • Iodine allergy
  • Contraindication to receiving radiotherapy, unless undergoing surgery
  • Pregnant

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Stanford University School of MedicineStanford, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 17, 2018. Always confirm current availability with the study team.

View original record ↗